T. Kristof

发表

Association of adherence to therapy and complementary and alternative medicine use with demographic factors and disease phenotype in patients with inflammatory bowel disease.

F. Nagy, M. Papp, P. Lakatos, 2010, Journal of Crohn's & colitis.

[Treatment adherence and use of complementary and alternative medicine in patients with inflammatory bowel disease].

T. Molnár, M. Papp, P. Lakatos, 2010, Orvosi hetilap.

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

Presymptomatic diagnosis of familial colon polyposis.

B. Nagy, Z. Papp, G. Gerö, 1997, Acta biologica Hungarica.

Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role?

K. Farkas, T. Molnár, M. Papp, 2016, Journal of Crohn's & colitis.

Long-term Efficacy, Safety, and Immunogenicity of Biosimilar Infliximab After One Year in a Prospective Nationwide Cohort

K. Farkas, F. Nagy, T. Molnár, 2017, Inflammatory bowel diseases.

Ferric maltol therapy for iron deficiency anaemia in patients with inflammatory bowel disease: long‐term extension data from a Phase 3 study

J. Mansfield, Fraser Cummings, T. Molnár, 2016, Alimentary pharmacology & therapeutics.

Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.

Teck Kiang Tan, J. Mansfield, Fraser Cummings, 2021, The lancet. Gastroenterology & hepatology.

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort

K. Farkas, F. Nagy, T. Molnár, 2017, Expert opinion on drug safety.

Final Results on Immunogenicity Profile and Predictors of ADA Development of Biosimilar Infliximab During the First 12 Months of the Therapy: Results from a Prospective Nationwide Cohort

K. Farkas, T. Molnár, M. Papp, 2017 .

P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort.

T. Molnár, M. Papp, P. Lakatos, 2017, Journal of Crohn's & colitis.

P331 Final results on efficacy and safety of biosimilar infliximab after one-year: results from a prospective nationwide cohort.

F. Nagy, T. Molnár, M. Papp, 2017, Journal of Crohn's & colitis.

Biosimilar Infliximab in inflammatory bowel diseases: First interim results from a prospective nationwide observational cohort

F. Nagy, M. Papp, P. Lakatos, 2015 .

Tu1348 Biosimilar Infliximab in Inflammatory Bowel Diseases: First Interim Results From a Prospective Nationwide Observational Cohort

K. Farkas, T. Molnár, M. Papp, 2015 .

Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.